Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Conversely, this group demonstrated increased sensitivity to cholecalciferol, olaparib, PRL-3 inhibitor, bicalutamide, and so on, which provides a reliable idea for future precise drug treatment of liver cancer (Fig. 3).

Source: Drug sensitivity analysis of SMARCAL1 in liver cancer. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The Cancer Genome Atlas (TCGA)-Liver Hepatocellular Carcinoma (LIHC) cohort data were downloaded from TCGA database, and the RNAseq and corresponding clinical data of patients were extracted.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Integrated multi-omics analysis reveals that SMARCAL1 serves as an immune related prognostic marker and promotes liver cancer growth

Study design awaiting verification · International Journal of Surgery (London, England) · 2026

Original publication title

Integrated multi-omics analysis reveals that SMARCAL1 serves as an immune related prognostic marker and promotes liver cancer growth

Tingting Huang; Meng Tang; Qiulin Tang; Di Ye; Jiayu Wang; Yichun Duan; Chenliang Zhang; Feng Bi

Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Targeting SMARCAL1 could be a promising strategy for liver cancer treatment.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To illustrate the potential role of SMARCAL1 in malignancy, immune regulation, and related pathway in liver cancer.

Source: Objective:

Abstract: What methods does the paper describe?

In our study, we examined the expression patterns, clinical features, and survival analysis from The Cancer Genome Atlas and GEO datasets. Immunedeconv package was employed for evaluating the association between the immune infiltration components and SMARCAL1 expression. Knockdown experiment was performed to examine the impacts of SMARCAL1 on cell viability, apoptosis, and classical Hippo-YAP pathway. Meanwhile, the association between SMARCAL1 expression and drug sensitivity was constructed through CTRP, PRISM, and GDSC databases. Finally, we also discovered novel inhibitors of SMARCAL1 activity against liver cancer and YAP activity through virtual screening and western blot assay.

Source: Methods:

Abstract: Results

SMARCAL1 exhibited increased expression in liver cancer (LIHC) and was linked to unfavorable outcomes for patients. SMARCAL1 expression was associated with specific clinical features, drug sensitivity, and immune microenvironment characteristics. Additionally, SMARCAL1 was closely related to the activity of Hippo-YAP pathway. Finally, deferoxamine mesylate and its parent compound deferoxamine were identified as candidate inhibitors of SMARCAL1 activity, showing significant ability to inhibit proliferation and the downstream protein YAP1.

Source: Results:

Abstract: Conclusion

Targeting SMARCAL1 could be a promising strategy for liver cancer treatment.

Source: Conclusion:
Authors’ abstract

Objective:

To illustrate the potential role of SMARCAL1 in malignancy, immune regulation, and related pathway in liver cancer.

Methods:

In our study, we examined the expression patterns, clinical features, and survival analysis from The Cancer Genome Atlas and GEO datasets. Immunedeconv package was employed for evaluating the association between the immune infiltration components and SMARCAL1 expression. Knockdown experiment was performed to examine the impacts of SMARCAL1 on cell viability, apoptosis, and classical Hippo-YAP pathway. Meanwhile, the association between SMARCAL1 expression and drug sensitivity was constructed through CTRP, PRISM, and GDSC databases. Finally, we also discovered novel inhibitors of SMARCAL1 activity against liver cancer and YAP activity through virtual screening and western blot assay.

Results:

SMARCAL1 exhibited increased expression in liver cancer (LIHC) and was linked to unfavorable outcomes for patients. SMARCAL1 expression was associated with specific clinical features, drug sensitivity, and immune microenvironment characteristics. Additionally, SMARCAL1 was closely related to the activity of Hippo-YAP pathway. Finally, deferoxamine mesylate and its parent compound deferoxamine were identified as candidate inhibitors of SMARCAL1 activity, showing significant ability to inhibit proliferation and the downstream protein YAP1.

Conclusion:

Targeting SMARCAL1 could be a promising strategy for liver cancer treatment.

Publication and source details

Original title: Integrated multi-omics analysis reveals that SMARCAL1 serves as an immune related prognostic marker and promotes liver cancer growth

Tingting Huang; Meng Tang; Qiulin Tang; Di Ye; Jiayu Wang; Yichun Duan; Chenliang Zhang; Feng Bi

International Journal of Surgery (London, England) · 2026

* Corresponding authors. Address: Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. Tel.: +86-15928448662. E-mail: zhangchenliang@wchscu.edu.cn (C. Zhang); Tel.: +86-18980601771. E-mail: bifeng@scu.edu.cn (F. Bi).Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc.2026https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:07:03.493317+00:00

DOI: 10.1097/js9.0000000000004567 · PMC13105517